Sigachi Industries Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jinzj9cxoaup2yro937q7rie.pdf

Key Takeaways


Revenue Trajectory & Back-End Loading

Sinha: "I would say that this in absolute terms would go up slightly, but overall I believe, the sales would increase and in percentage terms, this will drop at a later quarter."

Margin Dynamics


Segment & Product Updates

SegmentTrendCommentary
MCC (core excipient)▬ SteadyPrice grew modestly 1.07% YoY to ₹210.8/Kg; quantity grew 3.63% YoY to 7,307 MT in H1 FY24. Niche product with 60 grades.
API subsidiary▲ RampingAcquired Karnataka unit consolidated from August 1; integration ongoing. Target product lines and chemistry being firmed up; regulatory approvals from European Directorate and US FDA are key next steps.
Food & Nutrition▲ BuildingSupplementary product line sold to existing cellulose customers needing label-claim ingredients. Focus is on bulk business across continents, not domestic. Product approvals take time; samples sometimes need resubmission.
CCS▼ Pre-revenueGujarat Microwax is the predominant leader; CCS has large imports. Sigachi's PLI application awaits environmental clearance, expected December 2023. Commissioning takes 18 months from clearance.

Joint Ventures & International Expansion

Sinha: "The joint venture with our Saudi partner SNP (Saudi National Projects and Investments) is a very ambitious project with a very ambitious and good partner of Saudi."

Capacity Expansion & CapEx

Sinha: "We don't wait for a perfect situation for taking the first step. We look out for opportunities and jump in into opportunities even if there is a bit of ambiguity because when the ambiguity clears and when the things are crystal clear, there will be big players who would have already been kilometers ahead of us."

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 revenue₹400 croresFY24
API revenue~₹60 croresFY24
MCC expansion commissioningCommissioning activities commenceEnd of Q3 FY24
MCC expansion sales contribution25% of added capacityQ4 FY24
Employee cost stabilizationStabilization beginsQ4 FY24 onward
CCS environmental clearanceClearance receivedDecember 2023
CCS commissioning18 months from clearance~Mid-2025
API subsidiary CapExAdditional CapEx commences~3 months from now
Top-line growth (excipient business)25% increaseCurrent running business
3-5 year top-line growthAt least 25% year-on-yearNext 3 to 5 years
EBITDA marginPositive side of 20%All throughout
Sinha: "I'm looking at at least a 25% growth year-on-year over the next 3 to 5 years."

Key Metrics

MetricQ2 FY24
Operating income₹99 cr, +20.2% YoY
EBITDA₹21 cr, +31.2% YoY
EBITDA margin21.57%
Net profit~₹15 cr, +11% YoY
PAT margin15.22%
H1 FY24 operating income~₹184 cr, +14.4% YoY
H1 FY24 EBITDA₹37.8 cr, +16% YoY
H1 FY24 EBITDA margin20.55%
H1 FY24 net profit₹26 cr, -1.5% YoY
H1 FY24 PAT margin14.14%
H1 FY24 overall revenue₹186.62 cr, +13.37% YoY from ₹164.61 cr
MCC price H1 FY24₹210.8/Kg, +1.07% YoY from ₹208.55/Kg
MCC quantity H1 FY247,307 MT, +3.63% YoY from 7,051 MT
Sale of products H1 FY24₹166.46 cr, from ₹149.95 cr in H1 FY23
Employee cost₹14.73 cr, up from ~₹12.8 cr in Q1 FY24
API subsidiary top line (Aug–Sep)~₹7.5 cr, since acquisition on 1 Aug 2023
Total capacities>13,800 tonnes per annum, being enhanced to ~21,000 MTPA
FY24 revenue guidance₹400 cr, maintained
7,000 MTPA CapEx ramp-up25% of added capacity targeted in Q4 FY24; 10% in Q3 not expected
Other current liabilities H1 FY24₹118 cr, up from ₹9.4 cr due to provision for Trimax acquisition consideration
Medium-term top-line growth targetAt least 25% YoY over the next 3 to 5 years